Rznomics Inc, a biopharmaceutical company specialising in the development of RNA-based gene therapies, announced that the European Commission (EC) has granted orphan medicinal product designation to Rznomics’ taspitimagene advec (RZ-001), its RNA-editing gene therapy for the treatment of glioma.
The designation follows the positive opinion adopted in September 2026 by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency’s (EMA). This marks RZ-001’s first regulatory designation in Europe and further strengthens its development foundation across the two major markets of the United States and Europe.
Orphan medicinal product designation is intended to encourage the development of medicines for rare, serious, or life-threatening conditions. The programme offers regulatory and development benefits, including the possibility of market exclusivity following approval, reduced development fees, and support to enhance clinical development efficiency for orphan drugs.
RZ-001 has also secured several regulatory designations from the US Food and Drug Administration (FDA), supporting its development prospects and potential partnering value. The FDA has granted Orphan Drug Designation and Fast Track designation for RZ-001 for treatment of hepatocellular carcinoma (HCC) and glioblastoma (GBM). In addition, RZ-001 received Regenerative Medicine Advanced Therapy (RMAT) designation for HCC in May 2026.
Rznomics aims to advance global partnerships and expand the commercial potential of RZ-001. In addition to HCC and GBM, which are currently under clinical development, the company is pursuing expansion into additional solid tumour indications.
